Endocyte Inc.intends to use a deal to acquire worldwide rights for the prostate cancer therapeutic 177 Lu-PSMA-617 from ABX SA in Germany as a springboard for building a pipeline of radioligand therapeutics.
Endocyte described the deal in a statement as "transformational… accelerating our path to commercialization." The company is looking to get...








